The kinetics and regional distribution of [lIC]carfentanil, a fl.-selective opiate receptor agonist, and [lIC]diprenorphine, a nonselective opiate receptor antagonist, were compared using paired positron emis sion tomography studies in two normal volunteers. Ki netics of total radioactivity (counts/mCi/pixel) was greater for [lIC] Opiate receptors mediate the diverse effects of endogenous and exogenous opioids, including res piratory depression, analgesia, reward, euphoria, and sedation. Pharmacologic (Martin, 1967; Martin et aI., 1976) and in vitro (Lord et aI., 1977; Chang et aI., 1979; Goodman et aI., 1980; Wood, 1982; Tem pel and Zukin, 1987) binding studies suggest that multiple opiate receptors (j-L, 8, K) are responsible for these diverse effects. Subclasses of j-L-and K-opiate rt<ceptors have also been demonstrated and appear to be related to specific pharmacologic ac- 
to the thalamus (a region with known predominance of fl.-receptors), [lIC] diprenorphine displayed greater bind ing in the striatum and cingulate and frontal cortex com pared to [llC] carfentanil, consistent with labeling of ad ditional, non-fl. sites by [lIC] diprenorphine. We conclude from these studies that [IIC] diprenorphine labels other opiate receptor subtypes in addition to the fl. sites selec tively labeled by [llC] carfentanil. The nonselective na ture of diprenorphine potentially limits its usefulness in defining abnormalities of specific opiate receptor sub types in various diseases. Development of selective trac ers for the 0-and K-opiate receptor sites, or alternatively use of unlabeled inhibitors to differentially displace fl., 0, and K subtypes, will help offset these limitations. Key Words: Carfentanil-Diprenorphine-Opiate receptors Positron emission tomography.
tions (Goodman and Pasternak, 1985; Pasternak, 1986; Zukin et aI., 1988) . j-L]-Receptors are thought to mediate the analgesic effects of opiate agonists, whereas respiratory depression is thought to be pro duced through j-L2-receptors (Pasternak, 1986) .
Positron emission tomography (PET) has permit ted localization and quantification of opiate recep tors as well as other neurotransmitter receptors in the central nervous system and in the periphery (Wagner et aI., 1983; Frost et aI., 1984 Frost et aI., , 1985 Frost et aI., , 1986b Maziere et aI., 1985; Persson et aI., 1985; Samson et aI., 1985; Farde et aI., 1986; Frost, 1986; Mintun et aI., 1988; Smith et aI., 1988) . [llC] Carfentanil is a j-L-selective agonist and has been used to image j-L-opiate receptors by PET in humans (Frost et aI., 1985) . [llC] Carfentanil binding has been quantified in normal human subjects using tracer kinetic mod eling (Frost et aI., 1989a) , and increased [llC] car fentanil binding to j-L-opiate receptors in temporal lobe epilepsy has been demonstrated (Frost et aI., 1988) .
Opiate receptors were initially localized in vivo using autoradiography and eH]diprenorphine in rat brain (Pert et aI., 1975) and in monkey brain (Wam sley et aI., 1982) and later by PET in humans using [l1C]diprenorphine labeled in the cyclopropylme thyl (C20) group (Jones et aI., 1988) . Whereas car fentanil is selective for f.L-receptors, diprenorphine labels f.L-, 8-, and K-receptors with nearly equal af finity in vitro (Chang et aI., 1981; Pfeiffer et aI., 1982) . One study has suggested that eH]dipre norphine preferentially labels f.L-receptors in vivo in mouse brain (Frost et aI., 1986a) .
To quantify alterations in opiate receptor sub types in neurologic and psychiatric disorders, it is important to utilize subtype-selective ligands. Un fortunately, ligands are not yet available that can be used to selectively label 8-or K-receptors in vivo.
While e lC]diprenorphine may label 8-or K-re ceptors in addition to f.L-receptors in vivo, it suffers from the disadvantage of being nonselective.
The distribution of opiate receptors in human brain is receptor subtype specific. For example, while f.L-receptors are highly concentrated (relative to other subtypes) in thalamus and periaqueductal gray matter, 8-receptors are most concentrated in the basal ganglia and K-receptors in the cerebral cortex and amygdala (Pfeiffer et aI., 1982; Maurer et ai., 1983; Cross et aI., 1987) . The differential distri bution of f.L-, 8-, and K-receptors also permits iden tification of differences in receptor subtype binding in vivo by comparing binding in various regions. Since PET allows multiple studies to be performed in the same individual, the regional distribution of [l1C]carfentanil and e lC]diprenorphine can be di rectly compared. A difference in subtype specificity will be reflected as a difference in regional binding.
METHODS

Radiochemistry
[llC]Carfentanil and [llC]diprenorphine were synthe sized via the reaction of [llC]methyliodide, prepared from high specific activity [llC]carbon dioxide available from the Scanditronix RNP-16 biomedical cyclotron, and the appropriate nor-methyl precursor Lever et aI., 1987) . The synthesis produced, respec tively, [iiC] diprenorphine, radiolabeled in the 6-0-methyl group, and [llC]carfentanil, radiolabeled in the methyl group of the ester moiety. Both radioligands were deter mined to be radiochemically pure (>98%), sterile, and pyrogen-free by standard methods. The average specific activity of [iiC]diprenorphine prepared for these studies was 1,900 Ci/mmol and of P iC]carfentanil 2,400 Cilmmol, calculated at the time of injection.
PET studies
Two healthy men, 22 and 26 years old, were recruited through advertisement. These volunteers gave no history of neurological or psychiatric illnesses or of opiate or other drug ingestion. They provided informed consent in compliance with the Joint Committee on Clinical Inves tigation of the Johns Hopkins Medical Institutions.
Paired [IIC]carfentanil and [llC] diprenorphine PET studies were obtained on consecutive days in each sub ject. x-Ray computed tomography (CT) was used prior to the PET studies to identify a set of three imaging planes, 32 mm apart, parallel to the glabellar-inion line and pass ing through the amygdala and temporal cortex in the most caudal plane; the thalamus, striatum, and occipital cortex in the middle plane; and the frontal and parietal cortex in the most rostral plane. A thermoplastic face mask, with an alignment line drawn at the time of the CT scan, was used to ensure reproducible positioning between the CT and the two PET scans. PET studies were performed us ing the NeuroECAT scanner operating in the high resolution mode (Frost et aI., 1988) .
Subjects were administered -20 mCi of no more than 0.1 fLg/kg body weight of [llC]carfentanil or [llC]dipre norphine in each study. The specific activity ranged from 1,500 to 2,300 Ci/mmol for [IIC]diprenorphine and from 1,600 to 3,200 Ci/mmol for [llC]carfentanii. Two addi tional subjects were pretreated with naloxone (1.0 and 1.5 mg/kg) 10 min before the administration of [1IC]di prenorphine; these two subjects were also studied with [ttC]diprenorphine in the absence of naloxone. PET data were acquired beginning 30 s after tracer administration according to the following protocol: three 2-min scans, three 3-min scans, five 6-min scans, two ll-min scans, and one 21-min scan.
All PET images were corrected for attenuation using a calculation method with an average brain attenuation co efficient. ECAT counts were normalized to injected dose and corrected for radioactive decay. Images were summed from 35 to 70 min after injection for [llC] car fentanil studies to enhance anatomic detail for region of-interest (ROI) placement. ROIs were placed on paired left and right structures in the two hemispheres. Included in the analysis were the amygdala and temporal cortex in the lowest plane; the thalamus, striatum, and cingulate and occipital cortex in the middle plane; and the frontal and parietal cortex in the top plane. These ROIs were directly transposed to images summed from 50 to 90 min after injection for the corresponding [tiC]diprenorphine study. These sets of ROIs were also transferred to the images obtained at each time point for each ligand, cor responding to the acquisition protocol described above, to generate time-activity curves. Right and left values from each brain structure were averaged for subsequent analysis.
During the PET scans, the gantry angle and z-axis bed position were constantly monitored and adjusted to main tain precise positioning of the laser on the mask alignment line in order to correct for small movements of the sub ject's head. After the attenuation ellipses were placed, all images were translated and rotated such that the intersec tion of the axes of the ellipse was centered in the image matrix. These operations facilitated a close correspon dence of ROIs on the [1IC]carfentanil and [llC]dipre norphine images in each subject. Visual evaluation of the paired [tiC]carfentanil and P tC]diprenorphine images re-vealed no gross differences in positioning, as expected from the continuous monitoring of the alignment laser's position.
RESULTS
Figure 1 shows images obtained in one normal human subject using [llC]diprenorphine and [llC] _ carfentanil on the same day. Paired [1IC]car fentanil and [llC]diprenorphine studies were carried out in two normal subjects and similar results were obtained in both. Therefore, the kinetic data from only one subject are presented to demonstrate the differences in e lC]carfentanil and e lC]di prenorphine binding.
[llC]Carfentanil images were summed from 35 to 70 min after injection since the region/occipital cortex and regional/plasma ratios are maximal and nearly constant over this time (Frost et aI., 1988) . The [llC]diprenorphine images were summed from 50 to 90 min after injection since the region/occipital cortex ratio is high during this interval.
The two sets of images in Fig. 1 (Frost et al. , 1989c; unpublished data) .
These images were also quantified by ROI anal ysis in the two normal volunteers ( Figure 2 shows the kinetics of total radioactivity for ["C]carfentanil and [llC]diprenorphine in four representative structures: thalamus, caudate nu cleus, cingulate cortex, and temporal cortex. Counts are normalized to injected activity, time in terval for scan acquisition, and number of pixels. We have previously demonstrated that the nonspe cific binding of ["C]carfentanil can be adequately estimated from the occipital cortex (Frost et al. , 1989a) . ["C]Diprenorphine, on the other hand, has a significant number of binding sites in occipital cor tex (Pfeiffer et al. , 1982) . To accurately estimate nonspecific binding for ["C]diprenorphine in these studies, it was necessary to determine the percent age nonspecific binding in the occipital cortex at each time point. This was performed using nalox one in two additional normal male subjects, owing to radiation dosimetry concerns.
In Fig. 3A the kinetics of total and nonspecific binding in the occipital cortex for one representa tive subject is shown. In Fig. 3B the average per centage binding inhibited by 1 mg/kg naloxone is shown for the two subjects. The percentage remain ing represents the true nonspecific binding, and this value was subsequently used in the paired ["C]car fentanill["C]diprenorphine studies to generate the data in Figs. 4 and 5 .
["C]Carfentanil and ["C]diprenorphine binding in the thalamus, caudate nucleus, cingulate cortex, and temporal cortex was normalized to nonspecific activity and displayed as a function of time in Fig. 4 . In the case of ["C]carfentanil, the ratio increases rapidly and reaches a plateau after 40 min. In con trast, the ratio for [' 'C]diprenorphine increases more linearly until 60 min after injection and then begins to plateau. The ratio was higher for ["C] _ diprenorphine in all regions examined. Whereas [llC]carfentanil reaches near equilibrium between plasma and receptor binding (Frost et al. , 1988) , [llC]diprenorphine has not yet reached full equilib rium by 90 min (Frost et al. , 1989b) . Figure 5 shows the kinetics of the region minus nonspecific binding for thalamus, cingulate cortex, caudate nucleus, and temporal cortex. This differ ence approximates the kinetics of specific receptor binding. The kinetics of specific binding for ["C]carfentanil demonstrates rapid association and significant dissociation beginning at 30 min after in jection. By contrast, the kinetics of specific binding for ["C]diprenorphine demonstrates a slower asso ciation over the first 40 min and somewhat less dis sociation thereafter as compared to [" C]car- 
DISCUSSION
The major finding of this study is that e lC]dipre norphine and [l1C]carfentanil, a j.L-selective ligand, label different populations of opiate receptor sub types in vivo in the human brain. The high binding of [l1C]diprenorphine in thalamus, an area known to contain largely j.L-receptors (Pfeiffer et aI., 1982; Cross et aI., 1987) , suggests that diprenorphine does label j.L-receptors. The overall regional distribution of e lC]diprenorphine binding is not consistent with that of either j.L-, 8-, or K-receptors alone (Pfeiffer et aI., 1982; Cross et aI., 1987 total activity is greater for [11 Cjdiprenorphine than [1 1 Cjcarfentanil over the gO-min scanning period. The solid curves through the data points were drawn subjectively.
The results of this study point out the importance of recognizing receptor subtype specificity of ligands used for PET studies. Ideally, selective high-affinity 8-or K-selective ligands should be used in opiate receptor studies, but such ligands are not yet available for in vivo binding studies.
[l1C]Diprenorphine was employed in this study to determine if in vivo binding to opiate receptor sub types other than j.L-receptors could be observed at all. In principle, selective unlabeled antagonists for j.L-, 8-, and K-receptors could be used in sequence to displace the respective components of total [11C] _ diprenorphine binding. For example, studies could be performed using appropriate concentrations of selective j.L and 8 antagonists, permitting selective visualization of K-receptors using e lC]dipre norphine. However, selective 8 or K antagonists that can be safely administered to human subjects are also not yet available.
A previous study using a trace dose (1 j.Lg/kg) of eH]diprenorphine demonstrated preferential label ing of j.L-receptors in mouse brain using only in vivo binding methods (Frost et aI., 1986a) . Another study using a higher dose of [3H]diprenorphine and ex vivo methods in rat brain suggested binding to 8-and K-receptors as well as j.L-receptors (Richards and Sadee, 1985) . Clearly, there are species differ ences between humans and rodents in the number and distribution of opiate receptor subtypes, partic ularly K-receptors (Mansour et aI., 1988) . Factors such as receptor density, receptor subtype affinity, and modulation by ions and nucleotides, etc., could explain the in vivo binding differences between rat, mouse, and human brain. The total number of counts in the brain per mill icurie of [llC]diprenorphine administered is 1.5-to 2.0-fold greater compared to e lC]carfentanil for the various brain regions examined (Fig. 2) . Conse quently, the e lC]diprenorphine images demon strated better image quality due to improved count ing statistics compared to [llC]carfentanil images. Modeling studies are currently in progress to deter mine if the enhanced activity of [11C]diprenorphine is due to increased transport into brain, increased receptor binding, decreased metabolism, etc.
The apparent slow association and dissociation of diprenorphine are consistent with previous studies using e H]diprenorphine (Perry et al., 1980 (Wong et aI., 1986a,b) . Complete tracer kinetic modeling experiments and simulation studies, similar to those performed using [llC]car fentanil (Frost et aI., 1989a) , will help resolve these issues (Frost et aI., 1989b) .
[llC]Diprenorphine studies have also been per formed in human subjects using diprenorphine la beled at the C20 methylene group of the cyclopro pylmethyl moiety (Jones et aI., 1988) . Dissimilari ties in the behavior of diprenorphine labeled at these two positions could arise owing to differences in the clearance of differently labeled metabolites and/or possibly differences in the entry of the la beled metabolites into the brain. For example, in arterial plasma at 40 min after injection, only 40% of the total radioactivity is due to unmetabolized [llC]diprenorphine (J. J. Frost, unpublished data). Detailed comparisons of the two labeled forms of [11C]diprenorphine are not currently possible since tracer kinetic modeling to date has been applied only to [llC] diprenorphine labeled at the 6-O-methyl group (Frost et aI., 1989b) . Nonetheless, the data available suggest overall similarity of the two labeled forms of [llC]diprenorphine. The shapes of the total activity curves are similar, as are the ratios of specific to nonspecific activities at 60 min. Complete tracer kinetic modeling analysis of these two tracers would permit direct comparisons in the future.
The high specific activity attained in the current studies has permitted administration of significantly lower mass doses of [llC]diprenorphine: 0.05-0.1 compared with 0.3-0.5 )..L g/kg for diprenorphine la beled in the cyclopropylmethyl group (Jones et aI., 1988) . Total receptor occupancy was calculated us ing in vitro estimates of Bmax (Pfeiffer et aI., 1982) and in vivo modeling studies (Frost et aI., 1989b) . No more than 5% of the total opiate receptors are occupied in these studies. At doses of >0.1 )..L g/kg, significant numbers of opiate receptors become oc cupied. With increasing levels of partial saturation, the ratio of total to nonspecific binding in vivo will decrease, as observed in in vitro binding studies.
The current studies demonstrate that central opi ate receptors other than the )..L -receptor can be vi sualized in vivo by humans using PET. While e lC]diprenorphine is an attractive ligand owing to the high ratio of specific to nonspecific binding 
achieved, its nonselective properties in vivo will limit its usefulness in defining alterations in specific opiate receptor subtypes in health and disease. This problem will also be shared by other nonselective ligands developed for PET applications, including 18P-acetylcyclofoxy (Pert et aI., 1984; Rothman and McLean, 1988) . The use of selective unlabeled in hibitors to differentially displace j..L , 3, or K compo nents of e IC]diprenorphine may resolve the prob- TIME (min)
lem of receptor subtype nonselectivity to some ex tent, if they can be developed for human use. The non selectivity of [IIC]diprenorphine will also affect the ability to discriminate binding changes due to release of endogenous opioids. Some endogenous opioids are subtype specific (e.g., dynorphin), while others are not (e.g., Met-enkephalin). In most in stances, physiologic perturbations of interest are expected to alter the release of endogenous opioids � TIME (min)
selectively at a specific opiate receptor subtype. Thus, the development of selective positron emitting 8-and K-ligands for the in vivo labeling of opiate receptors remains highly desirable.
